Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials

BACKGROUND: Response rate (RR), the most common early means of assessing oncology drugs, is not suitable as the sole endpoint for phase II trials of drugs which induce disease stability but not regression. Time to progression (TTP) may be more sensitive to such agents, but induces recruitment delays...

Descripción completa

Detalles Bibliográficos
Autores principales: Goffin, John R, Pond, Greg R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259049/
https://www.ncbi.nlm.nih.gov/pubmed/22151297
http://dx.doi.org/10.1186/1471-2288-11-164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259049/
https://www.ncbi.nlm.nih.gov/pubmed/22151297
http://dx.doi.org/10.1186/1471-2288-11-164

Ejemplares similares